Clovis Oncology Net Income

The latest net income for CLVS is $-250M as of September 2022. That compares with $-300M in the prior-year period — up 15.8% year over year. That is below the Healthcare sector average of $17B. Investors often review this figure alongside Clovis Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, CLVS's net income moved from $-300M to $-250M — a 15.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Clovis Oncology's operating scale or balance-sheet position.

Against Healthcare companies, CLVS currently prints $-250M for net income, while the sector average sits near $17B. That is roughly 101.5% below the sector mean. Large gaps often invite a closer look at Clovis Oncology's growth, margins, and balance sheet.

A net income figure of $-250M for CLVS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $17B. Explore the charts below for those layers of context.

After noting CLVS's net income ($-250M), review year-over-year change from $-300M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.